Skip to main content
Erschienen in: International Ophthalmology 4/2021

22.01.2021 | Original Paper

Retinal layers in prolactinoma patients: a spectral-domain optical coherence tomography study

verfasst von: Berna Evranos Ogmen, Nagihan Ugurlu, Sevgül Faki, Sefika Burcak Polat, Reyhan Ersoy, Bekir Cakir

Erschienen in: International Ophthalmology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Prolactinoma is a type of pituitary tumour that produces an excessive amount of the hormone prolactin. It is the most common type of hormonally-active pituitary tumour. These tumours can cause ocular complications such as vision loss and visual fields (VF) defect. In this study, we aimed to evaluate the thickness of chorioretinal layers in patients with prolactinoma.

Methods

We enrolled 63 eyes of 32 prolactinoma patients and 36 eyes of 18 age and gender-matched healthy controls. All participants underwent complete hormonal and ophthalmological examination, including spectral-domain optical coherence tomography (SD-OCT) and VF test.The complete biochemical response was defined as serum PRL concentration ≤ 20 ng/mL at the time of evaluation.The seven layers were retinal nerve fibre layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), and retinal pigment epithelium (RPE). The results of prolactinoma patients were compared with the control group.

Results

The mean RNFL, GCL, IPL, INL, ONL, and RPE were thinner in prolactinoma patients than the control group (p < 0.05) while OPL was similar between groups (p > 0.05).None of the patients had VF defect.The thickness of retinal layers was similar in patients with and without complete biochemical response (p > 0.05).

Conclusion

To our knowledge, this is the first study that evaluates the thickness of chorioretinal layers in patients with prolactinoma.Most of the layers were thinner than the control group.Therefore, detailed eye assessment should be a routine component of the follow-up visits of prolactinoma patients and further studies related to this condition are required.
Literatur
1.
Zurück zum Zitat Miyai K, Ichihara K, Kondo K, Mori S (1986) Asymptomatic hyperprolactinaemia and prolactinoma in the general population–mass screening by paired assays of serum prolactin. Clin Endocrinol (Oxf) 25(5):549–554CrossRef Miyai K, Ichihara K, Kondo K, Mori S (1986) Asymptomatic hyperprolactinaemia and prolactinoma in the general population–mass screening by paired assays of serum prolactin. Clin Endocrinol (Oxf) 25(5):549–554CrossRef
3.
Zurück zum Zitat Dollar JR, Blackwell RE (1986) Diagnosis and management of prolactinomas. Cancer Metastasis Rev 5(2):125–138CrossRef Dollar JR, Blackwell RE (1986) Diagnosis and management of prolactinomas. Cancer Metastasis Rev 5(2):125–138CrossRef
7.
Zurück zum Zitat Asano S, Ueki K, Suzuki I, Kirino T (2001) Clinical features and medical treatment of male prolactinomas. Acta Neurochir (Wien) 143(5):465–470CrossRef Asano S, Ueki K, Suzuki I, Kirino T (2001) Clinical features and medical treatment of male prolactinomas. Acta Neurochir (Wien) 143(5):465–470CrossRef
8.
Zurück zum Zitat Nomikos P, Buchfelder M, Fahlbusch R (2001) Current management of prolactinomas. J Neurooncol 54(2):139–150CrossRef Nomikos P, Buchfelder M, Fahlbusch R (2001) Current management of prolactinomas. J Neurooncol 54(2):139–150CrossRef
9.
Zurück zum Zitat Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65(2):265–273. https://doi.org/10.1111/j.1365-2265.2006.02562.xCrossRef Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65(2):265–273. https://​doi.​org/​10.​1111/​j.​1365-2265.​2006.​02562.​xCrossRef
10.
Zurück zum Zitat Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA et al (1991) Optical coherence tomography. Science 254(5035):1178–1181CrossRef Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA et al (1991) Optical coherence tomography. Science 254(5035):1178–1181CrossRef
13.
Zurück zum Zitat Invernizzi A, Pellegrini M, Acquistapace A, Benatti E, Erba S, Cozzi M, Cigada M, Viola F, Gillies M, Staurenghi G (2018) Normative data for retinal-layer thickness maps generated by spectral-domain OCT in a white population. Ophthalmol Retina 2 (8):808–815 e801. https://doi.org/10.1016/j.oret.2017.12.012 Invernizzi A, Pellegrini M, Acquistapace A, Benatti E, Erba S, Cozzi M, Cigada M, Viola F, Gillies M, Staurenghi G (2018) Normative data for retinal-layer thickness maps generated by spectral-domain OCT in a white population. Ophthalmol Retina 2 (8):808–815 e801. https://​doi.​org/​10.​1016/​j.​oret.​2017.​12.​012
15.
Zurück zum Zitat Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group (1985). Arch Ophthalmol 103 (12):1796–1806 Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group (1985). Arch Ophthalmol 103 (12):1796–1806
16.
Zurück zum Zitat Ikeda H, Yoshimoto T (1995) Visual disturbances in patients with pituitary adenoma. Acta Neurol Scand 92(2):157–160CrossRef Ikeda H, Yoshimoto T (1995) Visual disturbances in patients with pituitary adenoma. Acta Neurol Scand 92(2):157–160CrossRef
18.
Zurück zum Zitat McIlwaine GG, Carrim ZI, Lueck CJ, Chrisp TM (2005) A mechanical theory to account for bitemporal hemianopia from chiasmal compression. J Neuroophthalmol 25(1):40–43CrossRef McIlwaine GG, Carrim ZI, Lueck CJ, Chrisp TM (2005) A mechanical theory to account for bitemporal hemianopia from chiasmal compression. J Neuroophthalmol 25(1):40–43CrossRef
19.
22.
Zurück zum Zitat Danesh-Meyer HV, Carroll SC, Foroozan R, Savino PJ, Fan J, Jiang Y, Vander Hoorn S (2006) Relationship between retinal nerve fiber layer and visual field sensitivity as measured by optical coherence tomography in chiasmal compression. Invest Ophthalmol Vis Sci 47(11):4827–4835. https://doi.org/10.1167/iovs.06-0327CrossRefPubMed Danesh-Meyer HV, Carroll SC, Foroozan R, Savino PJ, Fan J, Jiang Y, Vander Hoorn S (2006) Relationship between retinal nerve fiber layer and visual field sensitivity as measured by optical coherence tomography in chiasmal compression. Invest Ophthalmol Vis Sci 47(11):4827–4835. https://​doi.​org/​10.​1167/​iovs.​06-0327CrossRefPubMed
25.
Zurück zum Zitat RL R (2005) Visual function in Parkinson’s disease. In: Ebadi MPR (ed) Parkinson’s disease, 1st edn. Sigma, Turkey, pp 229–236 RL R (2005) Visual function in Parkinson’s disease. In: Ebadi MPR (ed) Parkinson’s disease, 1st edn. Sigma, Turkey, pp 229–236
26.
Zurück zum Zitat Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson’s disease. Invest Ophthalmol Vis Sci 31(11):2473–2475PubMed Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson’s disease. Invest Ophthalmol Vis Sci 31(11):2473–2475PubMed
27.
Zurück zum Zitat Bodis-Wollner I (1990) Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Trends Neurosci 13(7):296–302CrossRef Bodis-Wollner I (1990) Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Trends Neurosci 13(7):296–302CrossRef
28.
Zurück zum Zitat Lewis MM, Huang X, Nichols DE, Mailman RB (2006) D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson’s disease. CNS Neurol Disord Drug Targets 5(3):345–353CrossRef Lewis MM, Huang X, Nichols DE, Mailman RB (2006) D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson’s disease. CNS Neurol Disord Drug Targets 5(3):345–353CrossRef
29.
Zurück zum Zitat Jackson GR, Owsley C (2003) Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 21(3):709–728CrossRef Jackson GR, Owsley C (2003) Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 21(3):709–728CrossRef
30.
Zurück zum Zitat Yavas GF, Yilmaz O, Kusbeci T, Ozturk F (2007) The effect of levodopa and dopamine agonists on optic nerve head in Parkinson disease. Eur J Ophthalmol 17(5):812–816CrossRef Yavas GF, Yilmaz O, Kusbeci T, Ozturk F (2007) The effect of levodopa and dopamine agonists on optic nerve head in Parkinson disease. Eur J Ophthalmol 17(5):812–816CrossRef
33.
Zurück zum Zitat Chuman H, Cornblath WT, Trobe JD, Gebarski SS (2002) Delayed visual loss following pergolide treatment of a prolactinoma. J Neuroophthalmol 22(2):102–106CrossRef Chuman H, Cornblath WT, Trobe JD, Gebarski SS (2002) Delayed visual loss following pergolide treatment of a prolactinoma. J Neuroophthalmol 22(2):102–106CrossRef
Metadaten
Titel
Retinal layers in prolactinoma patients: a spectral-domain optical coherence tomography study
verfasst von
Berna Evranos Ogmen
Nagihan Ugurlu
Sevgül Faki
Sefika Burcak Polat
Reyhan Ersoy
Bekir Cakir
Publikationsdatum
22.01.2021
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 4/2021
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-021-01701-8

Weitere Artikel der Ausgabe 4/2021

International Ophthalmology 4/2021 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.